← Back to Search

Anticoagulant

Heparin for Coronavirus

Phase 4
Waitlist Available
Research Sponsored by Frederick Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

This trial will test if nebulized heparin can help treat severe lung injury caused by COVID-19.

Eligible Conditions
  • Coronavirus
  • Acute Respiratory Distress Syndrome
  • Acute Lung Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean daily PaO2 to FiO2 ratio
Secondary outcome measures
Duration of mechanical ventilation
ICU length of stay
Incidence of adverse drug events
+1 more

Side effects data

From 2008 Phase 4 trial • 541 Patients • NCT00277394
9%
Urinary tract infection
8%
Haematoma
6%
Constipation
4%
Pain in extremity
4%
Diarrhoea
2%
Deep vein thrombosis
2%
Cardiac failure
1%
International normalised ratio increased
1%
Melaena
1%
Subcutaneous haematoma
1%
Coagulation time prolonged
1%
Left ventricular failure
1%
Multi-organ failure
1%
Fall
1%
Sudden death
1%
Death
1%
General physical health deterioration
1%
Lung neoplasm malignant
1%
Metastatic neoplasm
1%
Respiratory failure
1%
Pulmonary embolism
1%
Depression
1%
Anaemia
1%
Rectal haemorrhage
1%
Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Innohep®
Heparin

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nebulized HeparinExperimental Treatment1 Intervention
Heparin 5,000 units/mL Dose: 25,000 units Frequency: every 6 hours Duration: 10 days
Group II: PlaceboPlacebo Group1 Intervention
0.9% Sodium Chloride Dose: 5 mL Frequency: every 6 hours Duration: 10 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Heparin
FDA approved

Find a Location

Who is running the clinical trial?

Frederick HealthLead Sponsor
2 Previous Clinical Trials
535 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The LancetJournal
Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study
Chen, Nanshan, Min Zhou, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, Yang Qiu, et al.. 2020. “Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(20)30211-7.
The LancetJournal
Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China
Huang, Chaolin, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, et al.. 2020. “Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(20)30183-5.
Nature Reviews ImmunologyJournal
Immunopathogenesis of Coronavirus Infections: Implications for SARS
Dandekar, Ajai A., and Stanley Perlman. 2005. “Immunopathogenesis of Coronavirus Infections: Implications for SARS”. Nature Reviews Immunology. Springer Science and Business Media LLC. doi:10.1038/nri1732.
clinicaltrials.govStudy
Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury
Thomas Smoot, PharmD 2020. "Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04397510.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top